Therapeutic approaches to dermatotoxicity by sulfur mustard. I. Modulaton of sulfur mustard-induced cutaneous injury in the mouse ear vesicant model.
The mouse ear edema model is recognized for its usefulness in studying skin responses and damage following exposure to chemical irritants, and for evaluating pharmacological agents against chemically induced skin injury. We recently modified the mouse ear edema model for use with sulfur mustard (HD) and used this model to study the protective effect of 33 topically applied compounds comprising five pharmaceutical strategies (anti-inflammatories, protease inhibitors, scavengers/chelators, poly(ADP-ribose) polymerase (PARP) inhibitors, calcium modulators/chelators) against HD-induced dermatotoxicity. Pharmacological modulation of HD injury in mouse ears was established by a reduction in edema or histopathology (epidermal necrosis and epidermal-dermal separation) at 24 h following topical liquid HD exposure. Ten of the 33 compounds administered as single topical pretreatments up to 2 h prior to HD challenge produced significant reductions in edema. Five of these ten also produced significant reductions in histological endpoints. Three candidates (olvanil, indomethacin, hydrocortisone) showing protection at 24 h were evaluated further for 'extended protection' at 48 and 72 h after HD challenge and showed significant modulation of edema at 48 h but not at 72 h. Olvanil also showed significant reductions in histology at 48 and 72 h. Olvanil and indomethacin were shown to reduce significantly the edema at 24 h post-exposure when administered topically 10 min after HD challenge, with olvanil additionally protecting against epidermal necrosis. These results demonstrate prophylactic and treatment effects of pharmacological agents against HD-induced skin injury in an in vivo model and support the continued use of the mouse ear vesicant model (MEVM) for evaluating medical countermeasures against HD.
Casillas
R P
RP
United States Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010-5425, USA. casillasr@battelle.org
Kiser
R C
RC
Truxall
J A
JA
Singer
A W
AW
Shumaker
S M
SM
Niemuth
N A
NA
Ricketts
K M
KM
Mitcheltree
L W
LW
Castrejon
L R
LR
Blank
J A
JA
D000818:Animals; D001768:Blister / Q000139:chemically induced* / Q000503:physiopathology; D003879:Dermatologic Agents / Q000633:toxicity*; D004423:Ear / Q000473:pathology; D004487:Edema; D051379:Mice; D008954:Models, Biological; D009151:Mustard Gas / Q000633:toxicity*; D009336:Necrosis; D020011:Protective Agents / Q000494:pharmacology*; D012867:Skin / Q000187:drug effects / Q000473:pathology
D003879:Dermatologic Agents; D020011:Protective Agents; D009151:Mustard Gas